Targeting the interaction between PD-1 and PD-L1 is a promising strategy for cancer immunotherapy via using checkpoint inhibitors, such as anti-PD-1 antibodies (pembrolizumab and nivolumab) and anti-PD-L1 antibodies (atezolizumab) (113, 114). The gene discussed is CD274; the disease is cancer.